Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Fa
Post# of 73
(Total Views: 177)
Posted On: 02/14/2022 3:51:11 PM
Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference
- NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022
- Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion
- NMRD’s sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use
- NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch Limited
- NMRD recently announced launch of Miboko metabolic health program targeted at global employers and insurers
Dr. Faz Chowdhury, CEO of Nemaura Medical (NASDAQ: NMRD), recently presented at the H.C. Wainwright BioConnect Conference on January 10-13, 2022, where he discussed the growing diabetes problem and how Continuous Glucose Monitoring (“CGM”) devices can help patients manage symptoms and reverse the disease (https://nnw.fm/CMxES).
Nemaura is a medical technology company that develops affordable, non-invasive wearable diagnostic devices and digital tools for chronic disease management. The company is currently commercializing its sugarBEAT(R) and proBEAT(TM) non-invasive and flexible wearable glucose monitoring devices that provide insights to help diabetic and pre-diabetic people better prevent, manage, and reverse the onset of the disease.
During his presentation, Dr. Chowdhury revealed that there are over 463 million diabetes patients worldwide amid a growing market estimated at $150 billion. NMRD’s vision is to lead the industry in the prevention, management, and reversal of diabetes with low-cost, flexible, and user-friendly devices and health coaching programs.
Unlike traditional glucose monitoring methods, NMRD’s sugarBEAT(R) devices are non-invasive and use a well-established glucose oxidase enzyme methodology to convert glucose at the skin’s surface to an electric current signal. Low energy Bluetooth connectivity then sends this information to the complimentary phone app every five minutes, where it’s converted to a glucose value that is presented to the user. With these insights, users can make critical lifestyle decisions to help prevent or manage symptoms.
The company is currently commercializing sugarBEAT(R) and in December 2021 commenced shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to MySugarWatch Limited, its UK licensing partner. MySugarWatch Limited plans to market the devices to nearly 5 million diabetics and 13.6 million at-risk people in the UK with a subscription model that includes a coaching and management service (https://nnw.fm/Yf1kM). In addition, NMRD launched Beta trials of Miboko, a new metabolic health program targeted at global employers and insurers (https://nnw.fm/ew1Rt). as well as the direct to consumer market.
In 2011, NMRD initially created a single platform technology that measures blood markers at the skin’s surface and has since adapted the technology to develop non-invasive glucose-monitoring wearable devices. With a unique position at the intersection of both diabetes and weight loss markets, Nemaura is positioned favorably with its proprietary technology in the rapidly growing medical wearable device industry.
For more information, visit the company’s website at www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://nnw.fm/NMRD
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022
- Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion
- NMRD’s sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use
- NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch Limited
- NMRD recently announced launch of Miboko metabolic health program targeted at global employers and insurers
Dr. Faz Chowdhury, CEO of Nemaura Medical (NASDAQ: NMRD), recently presented at the H.C. Wainwright BioConnect Conference on January 10-13, 2022, where he discussed the growing diabetes problem and how Continuous Glucose Monitoring (“CGM”) devices can help patients manage symptoms and reverse the disease (https://nnw.fm/CMxES).
Nemaura is a medical technology company that develops affordable, non-invasive wearable diagnostic devices and digital tools for chronic disease management. The company is currently commercializing its sugarBEAT(R) and proBEAT(TM) non-invasive and flexible wearable glucose monitoring devices that provide insights to help diabetic and pre-diabetic people better prevent, manage, and reverse the onset of the disease.
During his presentation, Dr. Chowdhury revealed that there are over 463 million diabetes patients worldwide amid a growing market estimated at $150 billion. NMRD’s vision is to lead the industry in the prevention, management, and reversal of diabetes with low-cost, flexible, and user-friendly devices and health coaching programs.
Unlike traditional glucose monitoring methods, NMRD’s sugarBEAT(R) devices are non-invasive and use a well-established glucose oxidase enzyme methodology to convert glucose at the skin’s surface to an electric current signal. Low energy Bluetooth connectivity then sends this information to the complimentary phone app every five minutes, where it’s converted to a glucose value that is presented to the user. With these insights, users can make critical lifestyle decisions to help prevent or manage symptoms.
The company is currently commercializing sugarBEAT(R) and in December 2021 commenced shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to MySugarWatch Limited, its UK licensing partner. MySugarWatch Limited plans to market the devices to nearly 5 million diabetics and 13.6 million at-risk people in the UK with a subscription model that includes a coaching and management service (https://nnw.fm/Yf1kM). In addition, NMRD launched Beta trials of Miboko, a new metabolic health program targeted at global employers and insurers (https://nnw.fm/ew1Rt). as well as the direct to consumer market.
In 2011, NMRD initially created a single platform technology that measures blood markers at the skin’s surface and has since adapted the technology to develop non-invasive glucose-monitoring wearable devices. With a unique position at the intersection of both diabetes and weight loss markets, Nemaura is positioned favorably with its proprietary technology in the rapidly growing medical wearable device industry.
For more information, visit the company’s website at www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://nnw.fm/NMRD
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Nemaura Medical Inc. (NMRD) Stock Research Links
Scroll down for more posts ▼